Systems and methods for treating blood clots with nerve stimulation

Patent metadata

Field	Value
Publication number	US-12469610-B2
Application number	US-202217944131-A
Country	US
Kind code	B2
Filing date	Sep 13, 2022
Priority date	Dec 22, 2017
Publication date	Nov 11, 2025
Grant date	Nov 11, 2025

Abstract

Systems and methods are provided for treating blood clots associated with a replicating pathogen, such as a virus in the coronaviridae family. The methods include emitting an electrical impulse near a vagus nerve within the patient sufficient to inhibit or reduce an inflammatory or allergic response in the patient, provide relief for bronchoconstriction that results in the tightening of airways and the inability to breath without ventilator support and/or lessen the abnormal blot clotting that develops in some patients. The systems and methods are particularly useful for treating post-COVID conditions or post-acute sequelae of COVID-19 that develop in “long-haul” or COVID patients.

First claim

The invention claimed is:

1 . A method for treating blood clots in a patient, the method comprising:
positioning a contact surface of a device in contact with an outer skin surface of a neck of the patient; applying, via the device, when the contact surface is in contact with the outer skin surface of the patient, an electrical impulse transcutaneously, via the contact surface, through the outer skin surface of the patient to a cervical branch of the vagus nerve of the patient; wherein the electrical impulse has a frequency of about 1 kHz to about 20 kHz and is sufficient to reduce a number of autoantibodies associated with blood clotting, to reduce a level of blood clotting in the patient; and applying the electrical impulse to the patient according to a treatment paradigm, wherein the treatment regimen consists of applying the electrical impulse to the patient as a first single dose for a time period of about 90 seconds to about 2 minutes and a second single dose for a time period of about 90 seconds to about 2 minutes, wherein the second single dose is applied five minutes or less after the first single dose and, wherein the first and second doses are each applied about 2 to about 12 times per day.

2 . The method of claim 1 , wherein the electrical impulse is sufficient to reduce a level of D-dimer in a blood of the patient.

3 . The method of claim 2 , wherein the level of D-dimer is reduced by at least 200 ng/mL.

4 . The method of claim 2 , wherein the level of D-dimer is reduced by at least 500 ng/mL.

5 . The method of claim 2 , wherein the D-dimer is associated with a presence of an antibody in the blood of the patient.

6 . The method of claim 1 , wherein the antibody is generated in response to a replicating pathogen.

7 . The method of claim 6 , wherein the replicating pathogen is a virus in the coronaviridae family.

8 . The method of claim 1 , wherein the autoantibodies include antibodies to phospholipids and phospholipid-binding proteins.

9 . The method of claim 1 , wherein the electrical impulse is sufficient to inhibit a release of a pro-inflammatory cytokine.

10 . A device for treating blood clots in a patient, the device comprising:
a housing having a contact surface for contacting an outer skin surface of a neck of the patient; a source of energy coupled to the housing for applying an electrical impulse transcutaneously, via the contact surface, through the outer skin surface of the patient to a cervical branch of the vagus nerve of the patient; wherein the electrical impulse comprises bursts of 2 to 20 pulses, with each burst having a frequency of about 15 Hz to about 50 Hz and each pulse having a frequency of about 1 kHz to about 20 kHz and is sufficient to reduce a number of autoantibodies associated with blood clotting, to reduce a level of blood clotting in the patient; and wherein the energy source is configured to apply the electrical impulse to the patient according to a treatment paradigm, wherein the treatment regimen consists of applying the electrical impulse to the patient as a first single dose for a time period of about 90 seconds to about 2 minutes and a second single dose for a time period of about 90 seconds to about 2 minutes, wherein the second single dose is applied five minutes or less after the first single dose and, wherein the first and second doses are each applied about 2 to about 12 times per day.

11 . The device of claim 10 , wherein the electrical impulse is sufficient to reduce a level of D-dimer in a blood of the patient.

12 . The device of claim 11 , wherein the D-dimer is associated with a presence of an antibody in the blood of the patient.

13 . The device of claim 11 , wherein the antibody is generated in response to a replicating pathogen.

14 . The device of claim 10 , wherein the device comprises one or more electrodes.

Assignees

• Electrocore Inc

Inventors

• Errico Joseph P
• Simon Bruce J
• Staats Peter
• Errico Thomas

Classifications

• A61N1/36

  for stimulation · CPC title

• A61N1/36053

  adapted for vagal stimulation (A61N1/36114 takes precedence) · CPC title

• A61N1/36034

  specified by the stimulation parameters · CPC title

• G16H70/60

  relating to pathologies · CPC title

• G16B35/00

  ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides · CPC title